OS Therapies (OSTX) vs Talphera (TLPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Talphera (TLPH) has outperformed OS Therapies (OSTX) over the past year, losing 41.4% versus a loss of 53.0%. OS Therapies is the larger company by market cap ($42.0 million vs $40.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OSTX | TLPH |
|---|---|---|
| Share price | $0.803 | $0.7852 |
| Market cap | $42.00M | $40.80M |
| 1-day change | -2.12% | +6.25% |
| YTD return | -42.64% | -31.12% |
| 1-year return | -53.04% | -41.40% |
| 5-year return | — | -93.96% |
| Forward P/E | 2.29 | — |
| EPS (TTM) | $-1.08 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $28.00K |
| Net income (latest FY) | $-28.75M | $-14.29M |
| Operating margin | — | -48157.14% |
| Net margin | — | -51035.71% |
| 52-week high | $2.25 | $1.57 |
| 52-week low | $0.58 | $0.69 |
| Distance from 52-week high | -64.31% | -49.99% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +958.53% | +298.62% |
| Average volume | 722.66K | 144.13K |
| Shares outstanding | 52.30M | 51.96M |
| Employees | 4 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLPH has outperformed OSTX by 11.6 percentage points over the past year.
About OS Therapies
OSTX stock →OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Talphera
TLPH stock →Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
OSTX vs TLPH FAQ
Which is bigger, OS Therapies or Talphera?
OS Therapies (OSTX) is larger, with a market capitalization of $42.00M compared with $40.80M for Talphera (TLPH).
Which stock has performed better over the past year, OSTX or TLPH?
TLPH returned -41.40% over the past 12 months, compared with -53.04% for OSTX (price return, excluding dividends). Past performance does not predict future results.
Are OS Therapies and Talphera in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.